New hope for kidney disease patients: finerenone trial aims to reduce protein leakage

NCT ID NCT07181135

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug finerenone can lower protein levels in the urine of people with chronic kidney disease who are not taking certain blood pressure medications. About 180 adults will receive either finerenone or a placebo for 6 months. The goal is to see if finerenone helps protect kidney function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria chronic kidney disease chronic renal failure syndrome kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Hospital Universitari Germans Trias i Pujol

    Barcelona, Spain

  • Hospital Universitario Dr Peset

    Valencia, Spain

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain

  • Hospital Universitario de La Princesa

    Madrid, Spain

  • Vall d'Hebron University Hospital

    Barcelona, Spain